
This article was downloaded by: [Universite Laval] On: 08 July 2014, At: 15:52 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/gpss20

Synthesis of the Novel Phosphoramidate Derivatives of Chrysin

Xiaolan Chen $^{\rm a}$, Jinwei Yuan $^{\rm a}$, Shouren Zhang $^{\rm a}$, Lingbo Qu $^{\rm a \, b}$ & Yufen Zhao $^{\rm a \, c}$

^a Key Laboratory of Organic Chemistry and Chemical Biology, Henan Province, Department of Chemistry , Zhengzhou University , Zhengzhou, P. R. China

^b Henan University of Technology, Henan Province, Zhengzhou, P. R. China

^c Key Laboratory for Bioorganic Phosphorus Chemistry and Chemical Biology, Ministry of Education, Department of Chemistry, School of Life Sciences and Engineering, Tsinghua University, Beijing, P. R. China

Published online: 03 Feb 2010.

To cite this article: Xiaolan Chen , Jinwei Yuan , Shouren Zhang , Lingbo Qu & Yufen Zhao (2010) Synthesis of the Novel Phosphoramidate Derivatives of Chrysin, Phosphorus, Sulfur, and Silicon and the Related Elements, 185:2, 274-278

To link to this article: <u>http://dx.doi.org/10.1080/10426500902772858</u>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &

Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions



Phosphorus, Sulfur, and Silicon, 185:274–278, 2010 Copyright © Taylor & Francis Group, LLC ISSN: 1042-6507 print / 1563-5325 online DOI: 10.1080/10426500902772858

SYNTHESIS OF THE NOVEL PHOSPHORAMIDATE DERIVATIVES OF CHRYSIN

Xiaolan Chen,¹ Jinwei Yuan,¹ Shouren Zhang,¹ Lingbo Qu,^{1,2} and Yufen Zhao^{1,3}

¹Key Laboratory of Organic Chemistry and Chemical Biology, Henan Province, Department of Chemistry, Zhengzhou University, Zhengzhou, P. R. China ²Henan University of Technology, Henan Province, Zhengzhou, P. R. China ³Key Laboratory for Bioorganic Phosphorus Chemistry and Chemical Biology, Ministry of Education, Department of Chemistry, School of Life Sciences and Engineering, Tsinghua University, Beijing, P. R. China

A novel type of phosphoramidate derivatives of chrysin were synthesized by a facile phosphorylation reaction. The structures of all the newly synthesized chrysin derivatives were confirmed by ESI MS, HR MS, NMR, and IR.

Keywords 5,7-Dihydroxyflavone; phosphoramidates; phosphorylation


INTRODUCTION

5,7-Dihydroxyflavone (chrysin), extensively distributed in plants, has been reported to have many biological activities, including antioxidant, antibacterial, anticancer, antiinflammatory, anti-allergenic, and anxiolytic antivities.^{1–6} Efforts to improve the biological activity of chrysin have led to the development of its derivatives by appropriate modification of chrysin as mentioned in some previously published articles.^{7,8} The introduction of a phosphate group essentially changes the physical and chemical properties of the parent molecule, resulting in changes to the polarization and intermolecular bonding characteristics of that molecule.^{9–11} Moreover, phosphates and phosphoramidates were widely used as pro-drug moieties to enhance water solubility and have proven to be exceedingly important agents for anticancer and antiviral therapy.^{12–17}

Given the importance of this functional group to these properties and potential biological activities, arylalkoxy-amino acid phosphorochloridates are coupled with chrysin to provide the target compounds, aryl phosphoramidates of chrysin, in order to change the physical and chemical properties of the parent molecule and enhance its bio-availability. A novel type of phosphoramidate derivatives of chrysin was synthesized by a facile phosphorylated reaction (Scheme 1) for the first time. The structures of all the newly synthesized chrysin derivatives were elucidated by ESI MS, HR MS, NMR, and IR.

Received 18 September 2008; accepted 21 January 2009.

Address correspondence to Xiaolan Chen and Lingbo Qu, Key Laboratory of Organic Chemistry and Chemical Biology, Henan Province, Department of Chemistry, Zhengzhou University, Zhengzhou, 450052, P. R. China. E-mail: chenxl@zzu.edu.cn



Scheme 1 Synthesis of phosphoramidates of chrysin.

RESULTS AND DISCUSSION

In the synthesis of phosphoramidate derivatives of chrysin (4) (Scheme 1), phenol was first reacted with phosphorus oxychloride at low temperature in the presence of triethylamine to give phenyl dichlorophosphates (1). Then phenyl dichlorophosphates (1) were coupled to different *L*-amino acid ester hydrochloride salts to achieve phenyl aminophosphorochloridates (2), which were not further purified by chromatography. Chrysin (3) was reacted with phenyl aminophosphorochloridates (2) in THF to form phosphoramidate derivatives of chrysin (4) in the presence of triethylamine at room temperature. The structures of all the newly synthesized chrysin derivatives were confirmed by ESI MS, HR MS, NMR, and IR.

Phenyl aminophosphorochloridates (2) could react at two different reaction positions (7-OH and 5-OH) of chrysin (3). The results showed that the phosphorylation occurred chemselectively only at the 7-OH of chrysin and not at 5-OH. This conclusion was confirmed by the ¹³C NMR of compound 4d. For example, ¹³C NMR of compound 4d showed that the signals from 7-C at δ 155.83 (J = 6.3), 6-C at δ 104.01 (J = 6.4), and 8-C at δ 99.36 (J = 4.6) were split into doublets by the single phosphorus atom nearby, respectively. Whereas, the singles from 5-C at δ 162.17 and 10-C at δ 108.43 were not split, and only a singlet was observed. These facts explain that the phosphorylation proceeds chemselectively favoring attack at 7-OH of chrysin. The reason why the phosphorylation occurred at the 7-OH of chrysin may be due to the hydrogen bonding of 5-OH group with the carbonyl group.

Due to the stereochemistry at the chiral phosphorus center, the products 4a-4c were isolated as mixtures of diastereoisomers, which were not easily separated by column chromatography, but are readily distinguished by ³¹P NMR. These diastereoisomers displayed

two closely spaced signals by ³¹P NMR (e.g., **4a**, δ –2.98, –3.00). Moreover, the presence of phosphate diastereoisomers was also apparent in the ¹H NMR and ¹³C NMR spectra.

EXPERIMENTAL

All experiments involving water-sensitive compounds were conducted under scrupulously dry conditions. The solvents were dried by appropriate methods. IR spectra were recorded on a Shimadazu IR-408. ¹H, ¹³C, and ³¹P NMR spectra were recorded on a Bruker Avance DPX spectrometer operating at 400.13, 100.61, and 161.98 MHz, respectively, with ¹³C and ³¹P spectra being recorded proton-decoupled. All NMR spectra were recorded in CDCl₃ at room temperature ($20^{\circ}C \pm 3^{\circ}C$). ¹H and ¹³C chemical shifts are quoted in parts per million downfield from TMS. ³¹P chemical shifts are quoted in parts per million relative to an external 85% H₃PO₄ standard. *J* values refer to coupling constants, and signal splitting patterns are described as singlet (s), broad singlet (bs), doublet (d), triplet (t), quartet (q), multiplet (m), or combinations thereof. TLC was performed on silica gel plates and preparative chromatograph on columns of silica gel (200–300 mesh). HR MS were recorded on Q-Tof Micro.

General Procedure for the Synthesis of Phosphoramidates of Chrysin

A solution of phenol (50.0 g, 0.53 mol) in phosphorus oxychloride (48.7 mL, 0.53 mol) and anhydrous diethylether (200 mL) was stirred at -78° C. Anhydrous triethylamine (76 mL, 0.54 mol) was added dropwise to this solution for 30 min. The reaction mixture was then allowed to warm up to room temperature and stirred for 16 h. The precipitated triethylamine hydrochloride salt was filtered off, and the filtrate was evaporated to dryness under reduced pressure. The crude product of phosphorodichloridate (1) was obtained as a clear liquid.¹⁸

Phosphodichloridate (1) (1.05 g, 5.0 mmol) and the appropriate amino acid esters hydrochloric salt (5.0 mmol) were suspended in anhydrous dichloromethane. Anhydrous triethylamine was added dropwise at -78° C during 1 h, and then the reaction was left to warm to room temperature. After 5 h, the solvent was removed under reduced pressure, and the residue was washed with anhydrous ether and was filtered. The filtrate was evaporated to dryness under reduced pressure. The crude phosphochloridate (2) was obtained and used without further purification by the chromatography.¹⁸

Anhydrous triethylamine was added dropwise to a solution of the appropriate phosphorochloridate (2) (0.02–0.03 mol) and chrysin (3) (2.54 g, 0.01 mol) in anhydrous tetrahydrofuran at room temperature, and the reaction mixture was stirred for 6–10 h. The precipitated triethylamine hydrochloride salt was filtered off, and the filtrate was evaporated to dryness under reduced pressure. The crude product (4) was purified by column chromatography on silica gel (CH₂Cl₂/ CH₃OH = 1:10).

Compound 4a (C_{26}H_{24}NO_8P). Yield (56%); mp 157–158°C. ¹H NMR (400.13 MHz, CDCl₃) δ : 12.74, 12.73 (s, 1H, 5-H), 7.88–7.86 (m, 2H, 2',6'-H), 7.57–7.49 (m, 3H, C-3', 4', 5'), 7.38–7.18 (m, 5H, H-2'', 3'', 4'', 5'', 6''), 7.05 (s, 1H, 8-H), 6.71 (s, 1H, 3-H), 6.66, 6.63 (d, 1H, J = 2.0, 6-H), 4.20–4.11 (m, 3H, OCH₂, CH-NH), 4.09–4.03 (m, 1H, NH), 1.43, 1.42 (d, 3H, $J = 2.2, CH_3$ -CH), 1.27–1.23 (m, 3H, OCH₂CH₃). ¹³C NMR (100.61 MHz, CDCl₃) δ : 182.74 (C-4), 173.01 (d, J = 8.0, C=O), 164.67, 164.65 (C-2), 162.15, 162.12 (C-5), 157.02 (C-9), 156.01, 155.93 (d, J = 6.5, C-7), 150.41, 150.34

(d, J = 6.2, C-1''), 132.15 (C-3', 5'), 130.87 (C-1'), 129.83 (C-3'', 5''), 129.14 (C-4'), 126.40 (C-2', 6'), 125.39 (C-4''), 120.18, 120.13 (d, J = 4.7, C-2'', 6''), 108.34 (C-10), 106.03 (C-3), 104.05, 104.00 (d, J = 3.7, C-6), 99.37, 99.28 (d, J = 4.6, C-8). 61.79, 61.77 (OCH₂), 50.49 (CH-NH), 21.00 (CH₃), 14.07 (OCH₂CH₃). ³¹P NMR (CDCl₃) δ : -2.98, -3.00. IR(KBr) ν_{max} (cm⁻¹): 1257 (P=O), 3200 (NH). ESI MS *m*/*z*: 532 [M + Na]⁺. A molecular formula of C₂₆H₂₄NO₈P was determined from the molecular ion peak at 510.1318 *m*/*z* [M + H]⁺ (calc. 510.1318 for C₂₆H₂₄NO₈PH) obtained by HR MS.

Compound 4b (C₂₈H₂₈NO₈P). Yield (59%); mp 149–150°C. ¹H NMR (400.13 MHz, CDCl₃) δ : 12.77 (s, 1H, 5-H), 7.83 (d, 2H, J = 7.4, 2', 6'-H), 7.52–7.45 (m, 3H, C-3', 4', 5'), 7.37–7.27 (m, 4H, H-2", 3", 5", 6"), 7.20–7.16 (m, 1H, H-4"), 7.05 (s, 1H, 8-H), 6.70 (s, 1H, 3-H), 6.67, 6.62 (d, 1H, J = 2.0, 6-H), 4.38-4.33 (m, 1H, NH), 4.14-4.08(m, 1H, NH-CH), 3.68, 3.65 (s, 3H, OCH₃), 1.73-1.65 (m, 1H, CH-(CH₃)₂), 1.65-1.52 $(m, 2H, CH_2-CH-(CH_3)_2), 0.90, 0.88 (d, 6H, J = 3.7, CH-(CH_3)_2).$ ¹³C NMR (100.61) MHz, CDCl₃) δ : 182.69, 182.69 (C-4), 173.75, 173.69 (d, J = 4.0, C=0), 164.56, 164.54 (C-2), 162.05, 162.02 (C-5), 156.93 (C-9), 156.09, 156.04 (d, J = 3.7, C-7), 150.49, 150.43 (C-1"), 132.12 (C-3', 5'), 130.73 (C-1'), 129.75, 129.80 (C-3", 5"), 129.09 (C-4'), 126.32 (C-2', 6'), 125.30 (C-4''), 120.18, 120.09 (d, J = 5.0, C-2'', 6''), 108.21 (C-10), 105.90(C-3), 104.02, 103.95 (C-6), 99.34, 99.27 (d, *J* = 4.5, C-8), 53.38, 53.35 (NH-CH), 52.33, 52.28 (OCH₃), 43.57, 43.51 (d, J = 1.3, CH₂-CH-(CH₃)₂), 24.35, 24.28 (CH-(CH₃)₂), 22.68, 21.75 (CH–(CH₃)₂). ³¹P NMR (CDCl₃) δ : -2.23, -2.41. IR(KBr) ν_{max} (cm⁻¹): 1253(P=O), 3184(NH). ESI MS: m/z: 538[M + H]⁺, 1097[2M + Na]⁺. A molecular formula of $C_{28}H_{28}NO_8P$ was determined from the molecular ion peak at 538.1639 m/z [M + H]⁺ (calc.538.1631 for C₂₈H₂₈NO₈PH) obtained by HR MS.

Compound 4c (C_{29}H_{30}NO_8P). Yield (54%); mp 129–130°C. ¹H NMR (400.13 MHz, CDCl₃) δ : 12.71, 12.71 (s, 1H, 5-H), 7.83 (d, 2H, J = 7.0, 2', 6'-H), 7.52–7.45 (m, 3H, C-3', 4', 5'), 7.36–7.27 (m, 4H, 3'', 2'', 5'', 6''-H), 7.20–7.18 (m, 1H, 4''-H), 7.05 (d, 1H, J = 1.36, 8-H), 6.70 (s, 1H, 3-H), 6.67, 6.63 (d, 1H, J = 1.68, 6-H), 4.30 (d, 1H, J = 3.7, NH), 4.15–4.08 (m, 3H, NH–CH, OCH₂), 1.59–1.53 (m, 2H, CH₂–CH–(CH₃)₂), 1.26–1.19 (m, 3H, OCH₂CH₃), 0.91, 0.89 (d, 6H, J = 4.0, CH-(CH₃)₂). ¹³C NMR (100.61 MHz, CDCl₃) δ : 182.7 (C-4), 173.3, 173.2 (d, J = 4.1, C=O), 164.5 (C-2), 162.1, 162.0 (C-5), 156.9(C-9), 156.1 (d, J = 6, C-7), 150.5 (d, J = 1.7, C-1''), 132.1 (C-3', 5'), 130.8 (C-1'), 129.8, 129.7 (C-3'', 5''), 129.1 (C-4'), 126.3 (C-2', 6'), 125.3 (C-4''), 120.2, 120.1 (d, J = 4.5, C-8), 61.4, 61.5 (OCH₂), 53.5, 53.4 (NH–CH), 43.7, 43.6 (CH₂–CH–(CH₃)₂), 24.4, 24.3 (CH–(CH₃)₂), 22.7, 21.8 (C–CH–(CH₃)₂). ³¹P NMR (CDCl₃) δ : -2.16, -2.34. IR(KBr) ν_{max} (cm⁻¹): 1252 (P=O), 3188 (NH). ESI MS m/z: 574 [M + Na]⁺, 1125 [2M + Na]⁺. A molecular formula of C₂₈H₂₈NO₈P was determined from the molecular ion peak at 552.1782 *m*/z [M + H]⁺ (calc. 552.1787 for C₂₉H₃₀NO₈PH) obtained by HR MS.

Compound 4d (C_{24}H_{20}NO_8P). Yield (58%); mp 156–157°C. ¹H NMR (400.13 MHz, CDCl₃) δ : 12.75 (s, 1H, 5-H), 7.88–7.86 (m, 2H, 2', 6'-H), 7.56–7.50 (m, 3H, C-3', 4', 5'), 7.39–7.26 (m, 4H, H-2'', 3'', 5'', 6''), 7.23–7.19 (m, 1H, H-4''), 7.06, 7.06 (d d, 1H, J = 2.1, J = 1.0, 8-H), 6.71 (s, 1H, 3-H), 6.66, 6.65 (d d, 1H, J = 2.0, J = 0.6, 6-H), 3.92 (d, 2H, $J = 9.8, CH_2$ -NH), 3.75 (s, 3H, OCH₃). ¹³C NMR (100.61 MHz, CDCl₃) δ : 182.76 (C-4), 170.40 (d, J = 9.0, C=O), 164.71 (C-2), 162.17 (C-5), 157.05 (C-9), 155.83 (d, J = 6.3, C-7), 150.28 (d, J = 7.0, C-1''), 132.19 (C-3', 5'), 130.84 (C-1'), 129.91 (C-2'', 6''), 129.16 (C-4'), 126.42 (C-2', 6'), 125.51 (C-4''), 120.14 (d, J = 4.7, C-3'', 5''), 108.43 (C-10), 106.04 (C-3), 104.01 (d, J = 6.4, C-6), 99.36 (d, J = 4.6, C-8). 52.65 (OCH₃), 42.98

(CH₂-NH). ³¹P NMR (CDCl₃) δ : -2.77. IR(KBr) ν_{max} (cm⁻¹): 1252 (P=O), 3220 (NH). ESI MS: m/z: 504.0[M + Na]⁺. A molecular formula of C₂₄H₂₀NO₈P was determined from the molecular ion peak at 482.1008 m/z [M + H]⁺ (calc. 482.1005 for C₂₄H₂₀NO₈PH) obtained by HR MS.

Compound 4e (C₂₅H₂₂NO₈P). Yield (56%); mp 139–140°C. ¹H NMR (400.13 MHz, CDCl₃) δ : 12.75 (s, 1H, 5-H), 7.88 (d, 2H, J = 6.9, 2', 6'-H), 7.57–7.51 (m, 3H, H-3', 4', 5'), 7.39–7.19 (m, 4H, H-2'', 3'', 5'', 6''), 7.07 (d, 1H, J = 0.92, 8-H), 6.72 (s, 1H, 3-H), 6.66 (s, 1H, 6-H), 4.24–4.19 (m, 1H, CH₂–N<u>H</u>), 4.09 (d, 2H, J = 6.7, CH₂–NH), 3.89 (d d, 2H, $J = 9.2, 5.7, OCH_2$), 1.27 (t, 3H, $J = 7.2, CH_3$). ¹³C NMR (100.61 MHz, CDCl₃) δ : 182.77 (C-4), 170.00 (d, J = 7.9, C=O), 164.73 (C-2), 162.21 (C-5), 157.08 (C-9), 155.95 (d, J = 6.1, C-7), 132.19 (C-3', 5'), 130.90 (C-1'), 129.80 (C-2'', 6''), 129.17 (C-4'), 126.43 (C-2', 6'), 125.49 (C-4''), 120.15 (d, J = 5.0, C-3'', 5''), 108.46 (C-10), 106.08 (C-3), 104.02 (d, J = 6.6, C-6), 99.36 (d, J = 4.6, C-8), 61.93 (OCH₂), 43.13 (CH₂-NH), 14.12 (CH₃). ³¹P NMR (CDCl₃) δ : –2.42. IR(KBr) ν_{max} (cm⁻¹): 1252 (P=O), 3194 (NH). ESI MS: m/z: 496 [M + H]⁺, 518 [M + Na]⁺. A molecular formula of C₂₅H₂₂NO₈P was determined from the molecular ion peak at 496.1163 m/z [M + H]⁺ (calc. 496.1161 for C₂₅H₂₂NO₈PH) obtained by HR MS.

REFERENCES

- 1. M. Hecker, C. Preiss, P. Klemm, and R. Busse, Br. J. Pharmacol., 118, 2178 (1996).
- N. Qais, M. M. Rahman, M. A. Rashid, H. Koshino, K. Nagasawa, and T. Nakata, *Fitoterapia*, 67, 554 (1996).
- 3. S. Habtemariam, J. Nat. Prod., 60, 775 (1997).
- 4. R. J. Fishkin, Psychopharmacology, 132, 335 (1997).
- 5. F. L. Pearce, A. D. Befs, and J. Bienenstock, J. Allegy. Clin. Immunol., 73, 819 (1984).
- C.Wolfman, H. Viola, A. Paladini, F. Dajas, and J. H. Medina, *Pharmacol. Biochem. Behav.*, 47, 1 (1994).
- J. S. Shin, K. S. Kim, M. B. Kim, J. H. Jeong, and B. K. Kim, *Bioorg. Med. Chem. Lett.*, 9, 869 (1999).
- K. Suresh Babu, T. Hari Babu, P. V. Srinivas, K. Hara Kishore, U. S. N. Murthy, and J. Madhusudana Rao, *Bioorg. Med. Chem. Lett.*, 16, 221 (2006).
- H. K. Han, R. L. A. De Vrueh, J. K. Rhie, K. M. Y. Covitz, P. L. Smith, C. P. Lee, D. M. Oh, W. Sadee, and G. L. Amidon, *Pharmaceut. Res.*, **15**, 1154 (1998).
- 10. M. Sprecher, R. Breslow, R. Philosof-Oppenheimer, and E. Chavet, Tetrahedron, 55, 5465 (1999).
- X. L. Chen, L. B. Qu, W. F. Li, J. W. Yuan, and Y. F. Zhao, *Phosphorus, Sulfur, and Silicon*, 183, 603 (2008).
- 12. S. Chang, G. W. Griesgraber, P. J. Southern, and C. R. Wagner, J. Med. Chem., 44, 223 (2001).
- D. Egron, J. L. Imbach, G. Gosselin, A. M. Aubertin, and C. Perigaud, *J. Med. Chem.*, 46, 4564 (2003).
- 14. C. L. Freel Meyers and R. F. Borch, J. Med. Chem., 43, 4319 (2000).
- 15. S. J. Hecker and M. D. Erion, J. Med. Chem., 51, 2328 (2008).
- 16. R. Y. Chen and X. R. Chen, *Heteroatom Chem.*, 4, 587 (1993).
- 17. C. O. Raymundo, L. C. Marcela, and A. T. Ruben, Monatsh. Chem., 130, 1129 (1999).
- C. McGuigan, J. C. Thiery, F. Daverio, W. G. Jiang, G. Davies, and M. Mason, *Bioorg. Med. Chem.*, 13, 3219 (2005).